Arm 1 Device: suprapubic tube ex 2 day; Arm 2 Device: suprapubic tube ex 5 day; Arm 3 Device: transurethral catheter ex 5 day
Arm 1 Drug: antibody ch14.18; Arm 2 Drug: GM-CSF; Arm 3 Drug: IL-2 i.v.; Arm 4 Drug: IL-2 s.c.; Arm 5 Drug: Retinoic acid
Arm 1 Drug: Progesterone; Arm 2 Drug: Progesterone
Arm 1 Other: metabolic assessment; Arm 2 Other: physiologic testing; Arm 3 Procedure: biopsy; Arm 4 Procedure: computed tomography; Arm 5 Procedure: conventional surgery; Arm 6 Procedure: magnetic resonance imaging; Arm 7 Procedure: management of therapy complications; Arm 8 Procedure: psychosocial assessment and care; Arm 9 Procedure: quality-of-life assessment; Arm 10 Radiation: radiation therapy
Arm 1 electrical cardioversion of atrial fibrillation; Arm 2 defirbrillation of atrial fibrillation
Arm 1 Biological: botulinum toxin Type A; Arm 2 Drug: Placebo
Arm 1 Drug: Sorafenib (Nexavar, BAY43-9006)
Arm 1 Device: Excision plus Hyalobarrier; Arm 2 Procedure: Excision only
Arm 1 Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Arm 1 Drug: Palonosetron; Arm 2 Drug: Palonosetron; Arm 3 Drug: Ondansetron; Arm 4 Drug: Placebo to Ondansetron; Arm 5 Drug: Placebo to Ondansetron; Arm 6 Drug: Placebo to Palonosetron
Arm 1 Drug: Cetuximab
Arm 1 Drug: ponatinib; Arm 2 Drug: imatinib (Gleevec/ Glivec)
Arm 1 Drug: Teriparatide; Arm 2 Drug: Placebo; Arm 3 Dietary Supplement: Calcium supplementation; Arm 4 Dietary Supplement: Vitamin D supplementation
Arm 1 Drug: Arm A: single agent docetaxel; Arm 2 Drug: Arm B: Combination of ganetespib and docetaxel
Arm 1 Drug: Placebo; Arm 2 Drug: Abiraterone acetate; Arm 3 Drug: Prednisone/prednisolone
Arm 1 Drug: Mirabegron; Arm 2 Drug: Solifenacin succinate low dose; Arm 3 Drug: Solifenacin succinate high dose
Arm 1 Biological: LMB-9 immunotoxin
Arm 1 Drug: Zoledronic Acid
Arm 1 Drug: MEK162, MEK inhibitor; oral; Arm 2 Drug: Physician's choice chemotherapy
Arm 1 Drug: BAY85-3934; Arm 2 Biological: Darbepoetin alfa
Arm 1 Drug: ITCA 650 (Exenatide in osmotic mini pump)
Arm 1 Procedure: Reduced Intensity Conditioning Stem Cell Transplantation
Arm 1 Radiation: Radiation therapy
Arm 1 Drug: sabarubicin
Arm 1 2.0 mg/kg NOX-A12 IV every day for 5 days; Arm 2 4.0 mg/kg NOX-A12 IV every day for 5 days; Arm 3 5 µg/kg filgrastim SC every day for 5 days<br/>; Arm 4 Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days. Based on PD data, a simultaneous or sequential dosing will be chosen.
Arm 1 Conventional embolectomy/thrombectomy with uncontrolled reperfusion; Arm 2 Embolectomy/thrombectomy with controlled reperfusion
Arm 1 Drug: Cabazitaxel (XRP6258); Arm 2 Drug: Prednisone
Arm 1 Drug: POL7080
Arm 1 Drug: Ovarian stimulation in a GnRH-antagonist protocol
Arm 1 Patient with sepsis, tissue sampling of palatine tonsils; Arm 2 Patients with chronic tonsillitis, tissue sampling of palatine tonsils; Arm 3 Patients with tonsil hyperplasia, tissue sampling of palatine tonsils
Arm 1 Patients with Gastrointestinal Stromal Tumors undergoing tyrosine kinase inhibitor treatment will be assessed regarding progression-free survival and overall survival within 2 years using the standard response criteria, in particular Response Evaluation Criteria In Solid Tumors, the WHO criteria for response, the tumor lesion volume as well as tumor density (according to Choi).; Arm 2 Patients with Gastrointestinal Stromal Tumors undergoing  tyrosine kinase inhibitor treatment will be assessed regarding progression-free survival and overall survival within 2 years using the response criteria, in particular tumor lesion iodine uptake normalised to the aorta and tumor lesion iodine uptake normalised to the portal vein.
Arm 1 Intraindividual comparison of 3D transesophageal echocardiography measurements and MSCT (multidetector computed tomography) measurements for the selection of the appropriate valve prosthesis before transvascular transcatheter aortic valve replacement (TAVR)
Arm 1 Experimental Arm: <br/>Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions. <br/>To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software "Praxis-connect" i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.<br/>Patients who test positive for Copeptin will be treated as by standard practise.; Arm 2 Control Arm:<br/>Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.
Arm 1 Application of TXA for given indications such as severe trauma, severe gynecological bleeding, GI bleeding, TE rebleeding.<br/>We analyze emergency medical protocols for appropriate applications.<br/>To get indicators for other potential indications, we match possible indications with clinical laboratory data and medical reports.
Arm 1 Over a period of 6 weeks, the intervention group participants will listen to their individualized music playlist through headphones every other day for 20 minutes in the presence of employees of the nursing home or project staff. Observation of behavior will be conducted by the project staff every other week before, during and after the music intervention. <br/>; Arm 2 The control group receives standard care. The observation of behavior will be conducted with the same frequency and duration as in the intervention group.<br/>
Arm 1 Patients with diagnosed arterial hypertension. Patients undergo measurements of pulse wave velocity and peripheral blood pressure as well as ultrasound elastography of the aorta.; Arm 2 Healthy volunteers. Volunteers undergo measurements of pulse wave velocity and peripheral blood pressure as well as ultrasound elastography of the aorta.
Arm 1 The following parameters will be included in the individualized pharmacotherapeutical risk information:<br/> - genetical analysis (CYP2C9, CYP2C19, VCORC1)<br/>- drug- drug interaction test<br/>- liver values and other lab values<br/><br/>There will be no given direction to change the drug therapy. The doctor can act as he thinks is best for the patient. Every 3 month (3 times ) there will be consultations with the patient, where the patients will be ask about their general health. The patients will be ask the following questions, just to list a few:<br/>-  number of sick certifcates<br/>- number of specialist's referral<br/>- number of admissions to a hosital<br/>- accidents (traffic, in the house, at work,....)<br/>- operations<br/>- invasive examination (e.g. catheter)<br/>- allergic reactions<br/>- headache<br/>- nausea<br/>-.........<br/><br/>; Arm 2 Patients that get the standardized risk information will get informed in detail about their liver values and other values, that were measured in the lab. Also they will get detailed information again about the meaning of oral anticoagulation. The treatment will be according to current medical standards including additional standardized information on risk factors for adverse drug effects. Every 3 month ( 3 times altogteher) the patients are ask for their health status. the following paramters are being documented:<br/>-  number of sick certifcates<br/>- number of specialist's referral<br/>- number of admissions to a hosital<br/>- accidents (traffic, in the house, at work,....)<br/>- severe adverse drug reactions <br/>- Number of hospital admissions due to adverse drug effects<br/>- Number of specialist consultations due to problems in drug therapy<br/>- Number of medication changes during obsevation period<br/>- etc. ....<br/>
Arm 1 This prospective descriptive observational study evaluates the prevalence of simultaneous outletimpingement in patients with calcifying tendinitis, considering either the pre- and postoperative x-rays and also standardized intraoperative views from the shoulder arthroscopy of the next 60 patients with calcifying tendinitis which proved refractory to conservative treatment and who will be treated with shoulder arthroscopy in our clinic according to our standard treatment. The intraoperative subacromial views will be taken before and after the (as performed as a standard procedure in our clinic in these patients) arthroscopic subacromial decompression.<br/>For an evaluation of the outcome of our patients, they will get to fill out the established constant score-patient-questionnaire for self-evaluation; 3-6 months after the operation, we will do a telephone interview using the same questionnaire. In addition, we will evaulate the radiologic extent of removal of the calcification when intraoperative x-ray is used. We use intraoperative x-ray as a standard procedure during operations for calcifying tendinitis to be able to remove as much of the calcification as possible and to be able to definitely find and open all the calcifications. <br/><br/>50 of the patients that we planned for the study had complete data sets. <br/>During the study, we decided to add a second follow-up after a longer period of 1-2 years to increase the validity of the clinical outcome.
Arm 1 150-300mg / m bexarotene daily per os for at least 24 weeks
Arm 1 Temporary restoration made of Protemp 4; Arm 2 Temporary restoration made of Luxatemp® Automix Plus<br/>Reference data, retrospective comparison
Arm 1 Patient with cancer pain, Matrixstimulation, 4 Hz, 5 Minutes, Stimulation twice a day (morning and evening) on three consecutive days (day 1-3).
Arm 1 Monitoring of patients with scheduled transcatheter closure of Secundum Atrial Septal Defects (ASD II) with Ceraflex-ASD-Occluder
Arm 1 Single arm. Interventions: Questionnaires for patients and treating physicians. Collection of 10 mL EDTA blood (during routine checks) for resistance analysis
Arm 1 Test group: participants get grades in the courses of orthodontics- via the e-larning based portal Itunes U; Arm 2 Control group: participants receive the dichotomous test sheet and additionally grades in secret
Arm 1 use of gcs (graduated compression stockings); Arm 2 no use of gcs
Arm 1 Risk-adjusted analysis of standardized data from hospital reimbursement claims (§21-Datatset according to the German Law of Hospital Reimbursement (Krankenhausentgeltgesetz)) of patients with sepsis, severe sepsis and septic shock of participating hospitals. The quality reports for analyses are created every three months for all participating hospitals allowing individual case analyses, analyses according to departments, and anonymous benchmarking with all other participating hospitals and the German average.
Arm 1 initial vitrectomy with ILM-peeling with intraoperative andministration of Ranibizumab 0,5 mg intravitreally. After vitrectomy, 2 further injections of 0,5 mg Ranibizumab every 4 weeks will be performed, according to the label of Ranibizumab (Lucentis ®). After the first 3 obligatory treatments with Ranibizumab, examination will be performed every 4 weeks. Further injections will be given, according to the label of Ranibizumab (Lucentis ®), if indicated.; Arm 2 Three initial injections of 0,5 mg Ranibizumab every 4 weeks will be performed, according to the label of Ranibizumab (Lucentis ®). After the first 3 obligatory treatments with Ranibizumab, examination will be performed every 4 weeks. Further injections will be given, according to the label of Ranibizumab (Lucentis ®), if indicated
Arm 1 Intervention phase: Use of a digital paediatric drug information system,<br/>participation to regular paediatric-pharmacological quality circles,<br/>stimulated spontaneous reporting of adverse drug reactions and medication errors in outpatient paediatricians, psychiatrists and general practitioners<br/>; Arm 2 Control phase
Arm 1 Intake of Eusano formulation 3 capsules per day
Arm 1 The ACROSSS Study includes patients who have sufferred from a myocardial infarction, a stroke or a transient ischemic attack. The aim of the study is to answer two questions: First, to investigate whether the acute event has an impact on the patients´ sleep like worse sleep quality or taking a nap more often. Second, to investigate which factors might have triggered the acute event, e.g. a nap taken shortly before or the intake of certain drugs.<br/><br/>The following investigations will be carried out:<br/><br/>T1: First contact with the participants who have left the intensive care unit <br/>- questionnaires on sleep characteristics and sleep behaviour in the last 4 weeks before the index event<br/>- case-crossover questionnaire<br/>- questionnaire on comorbidities and confounders<br/>- questionnaire on functional restrictions<br/>- sleep apnea measurement (using the device Apnea Link)<br/><br/>T2: 3 months after the index event<br/>- questionnaires on sleep characteristics and sleep behaviour in the last 4 weeks<br/>- questionnaire on functional restrictions<br/>- drug history<br/>- measurement of sleep behaviour and daytime activity (using the device SOMNOwatch)<br/>- assessment of vital status via questionnaire (further myocardial infarction / stroke / TIA / death)<br/><br/>T3: 1 year after the index event<br/>- questionnaires on sleep characteristics and sleep behaviour in the last 4 weeks<br/>- questionnaire on functional restrictions<br/>- drug history<br/>- measurement of sleep behaviour and daytime activity (using the device SOMNOwatch)<br/>- assessment of vital status via questionnaire (further myocardial infarction / stroke / TIA / death)<br/><br/>T4: about 5 years after the index event<br/>- assessment of vital status including research on cause of death
Arm 1 Biological: Pembrolizumab; Arm 2 Drug: Axitinib; Arm 3 Drug: Sunitinib
Arm 1 Klacid® therapy
Arm 1 only one arm since study is an observational study.<br/>All patients with ARDS and a lung CT scan can be recruited into the  study. Automatic and manual lung CT analyses are performed and results compared.
Arm 1 controlled diet according to 20% energy fom fat of consumed food, as well as isoflavones following placebo; Arm 2 controlled diet according to 40% energy fom fat of consumed food, as well as isoflavones following placebo
Arm 1 In Patients, undergoing operative stabilization of the Patella before and after operative treatment a dynamic MRI of the knee joint, determining patellorfemoral kinematics will be carried out. ; Arm 2 Healthy people with a dynamic MRI of the knee joint, determining patellorfemoral kinematics will be carried out.
Arm 1 Drug: Pazopanib; Arm 2 Drug: 5-FU, Oxaliplatin, Leukovorin (FLO)
Arm 1 Based on a review of the literature and a manual that was developed in a former study, a training will be developed that enables teamleaders of rehabilitation clinics to act as team coaches in their teams. All participating teamleaders wil receive training, which will be evaluated by a questionnaire and interviews. They will apply the trained coaching tools in their teams. Members of the teams will be observed and questioned (by interviews and questionnaires) regarding teamwork parameters in order to measure the coachings' effects and mechanisms of change.
Arm 1 PVP-Hypericin instillation (225µg Hypericin) for 30+5 minutes, subsequently cystoscopy with white light followed by cystoscopy with blue light
Arm 1 just manual mask ventilation; Arm 2 mask ventilation via anesthesia machine
Arm 1 We will include 20 multiple sclerosis patients that are planned for alemtuzumab therapy in our study. <br/>For one year we will analyze monthly additional lab parameters during the mandatory blood drawls. <br/>
Arm 1 Inervention group (IG) with Eksoskeltt (Ekso Bionics): 45 minutes daily training from monday to friday for three weeks ; Arm 2 Control group (CG): 45 minutes daily training from monday to friday for three weeks in conventional physiotherapy programm which includes fasclitation, trunc controll training, at least 20min walking with personal and/or devices aid (with the exception of Ekso)
Arm 1 topical 3% polidocanol solution, one time application to the skin as spray, about 1ml in total; histamine prick (10mg/ml), 40 cowhage spicules rubbed on the skin for 40 seconds; Arm 2 placebo, one time application to the skin as spray, about 1ml in total; histamine prick (10mg/ml), 40 cowhage spicules rubbed on the skin for 40 seconds
Arm 1 Study participants receive successively the possibility to use current noise suppression NR2 and compare this to NR3 SpatialNR. There is no comparison with other Groups of noise Suppression algorithms.<br/>An intra-individual comparison will be performed.
Arm 1 best medical care; Arm 2 endovascular thrombectomy using a stent-retriever and best medical care
Arm 1 Cross over design. After baseline measurement of the expiratory flow, the flow will be limited in two steps (ca. 30% and ca. 60%; 3 min. each; randomised sequence). ; Arm 2 see Arm 1
Arm 1 Assessment of Overall Survival (OS) of all adult patients with a first histological diagnosis of diffuse low grade gliomas (DLGG) who were treated by either stereotactic biopsy or resection at the University Medical Center Freiburg between 2004 and 2012.
Arm 1 The lifetime stress burden should be studied in individuals with subjective cognitive impairment, mild cognitive impairment, and mild to moderate Alzheimer's dementia. The study will cover various types of stress across lifespan, including occupational stress (Fragebogen zu Intensität und Tätigkeitsspielraum, FIT), stress-associated personality traits (EPQR-K, neuroticism), incriminating life events (Life Events Checklist (LEC), as well as neglect and abuse experiences childhood (Childhood Trauma Questionnaire; CTQ). Cognition at the time of completing the questionnaires is recorded using the Clinical Dementia Rating Scale (CDR), Shulman´s clock drawing test and Consortium to Establish a Registry for Alzheimer's Disease (CERAD). In addition, routine clinical data such as CSF-derived dementia markers are also used in the study. Furthermore, mental, social and physical activities carried out over the lifespan are recorded and their connection to cognition are analyzed; Arm 2 The relatives of the participants are recruited as a cognitively healthy control group. The control group completes the same questionnaires as the patient group. To rule out cognitive deficits, participants are asked if they have noticed subjective cognitive deficits and the Shulman's clock drawing test is completed. In addition, medical conditions that could influence cognition are requested.
Arm 1 Detect Ischemia is an single center, prospective observational study. All patients with clinical indication for invasive coronary angiography and intermediate coronary artery stenosis will be evaluated by fractional flow reserve (FFR),  instantaneous wave-free ratio and quantitative flow Ratio measuerments.
Arm 1 After tumor excision wound treatment with Hyalomatrix (Anika Therapeutics S.r.l) followed by autologous skin graft; Arm 2 After tumor excision open wound treatment with Aqaucel (Convatec) followed by autologous skin graft
Arm 1 mobility program: monitored balancetraining in sitting and standing, walking on spot or in patients room, training sit to stand for a maximum of 30 min, 3-5 times/week, 2 weeks additionally to standard therapy; Arm 2 endurance training with a bedside-ergometer for a maximum of 30 min., 3-5 times/week, 2 weeks additionally to standard therapy
Arm 1 Other: Perfusion-CT
Arm 1 Assessment of physical performance (power, gait analysis, sit-to-stand transfer, grip strength, leg extension strength, balance) exposed to 15°C and 25°C in randomized order. Assessment of quality of life, cognition, depression, nutritional status, and thermal well-being by questionnaires. Assessment of physical activity by body-worn sensors and questionnaire. Assessment of muscle mass (thigh) by MRI. Blood samples (inflammatory markers) are taken at normal room temperature.
Arm 1 Drug: Pazopanib plus Gemcitabine; Arm 2 Drug: Pazopanib
Arm 1 We recruite thirty consecutive patients consulting our PCIW. During the first or second session, the therapist informes the patient about the study. If the patient gives written informed consent, he is handed out a questionnaire which he should fill in within a week. The questionnaire containes the  Work-Ability-Index Kurzform (WAI), Patient-Health-Questionnaire (PHQ), SF-12 (Short Form health questionnaire), Maslach-Burnout-Inventory (MBI-GS-D), and the Irritation Scale (IS). Diagnoses, medication, smoking status and BMI are obtained and documented by the therapist. To measure HRV, the patient receives a stingray and a one channel ECG device (eMotion Faros 180°, Mega Electronic) and he is shown how to use it. He is handed out the salivettes for measurement of cortisol in the saliva and is again shown how to use it. ECG measurement should start in the evening around 18 o'clock. Saliva is taken on the following day at 0, 15, 30, 45, 60 min., 6 and 8 hours after awakening and at bed time. At this day in the evening, the stingray is taken off. <br/>If indicated, the patient receives a short time therapy. It contains the following topics: identification of problematic schemes, focussing on one of them and working on alternative strategies; identification of ressources and strengthening of them; strenghthening of self efficacy by promoting sports and relaxation training. The second measurement (after the intervention) is done only in patients who received at least four sessions and is analogous to the first. Three months after intervention the patient is sent the same questionnaire again and he is contacted by telephone to remember to fill in the questionnaire.
Arm 1 Drug: Bortezomib
Arm 1 Treatment group: Patients with Social Phobia who got 25 sessions cognitive therapy à 50 minutes according to the manual of Stangier, Clark and Ehlers (2006) between the first and the second measuring time. At three measuring time (before therapy, after, therapy, 6-month-follow-up), the subjective and psychoneuroendrocrinologically stress response during the Trier Social Stress Test (Kirschbaum, Pirke, & Hellhammer, 1993) was investigated. ; Arm 2 Waitlist control group: Patients with Social Phobia who got no intervention between the first and the second measuring time. At three measuring time (before wait time, after wait time, 6-month-follow-up), the subjective and psychoneuroendrocrinologically stress response during the Trier Social Stress Test (Kirschbaum, Pirke, & Hellhammer, 1993) was investigated. ; Arm 3 Health controls: Healthy participants who got no intervention between the first and the second measuring time. At three measuring times (pre, after 4-6 month, 6-month-follow-up), the subjective and psychoneuroendrocrinologically stress response during the Trier Social Stress Test (Kirschbaum, Pirke, & Hellhammer, 1993) was investigated.
Arm 1 Members of statutory health insurance between 25 and 50 years living in Bavaria are invited to participate in the study. <br/>Based on a short questionnaire on their family history of colorectal cancer (CRC), which is a simplified version of the Amsterdam and Bethesda criteria, participants are classified as potential risk carrier or as risk free.  <br/>Participants with a family history of CRC can decide to undergo an iFOBT (fecal immunochemical test), a screening colonoscopy, or deferring further actions to a later point in life.<br/>Participants in arm 1 are study participants with a family history of CRC who decide for one of the proposed screening measures. ; Arm 2 Participants between 25 and 50 years living in Bavaria without family history of CRC; Arm 3 In arm 3, the incidence of CRC in members of statutory health insurance companies between 25 and 50 years of age living in Bavaria who do not participate in the study will be monitored through health administrative databases.
Arm 1 Drug: BAY85-3934; Arm 2 Drug: Placebo
Arm 1 Drug: AMG 386; Arm 2 Drug: Paclitaxel; Arm 3 Drug: AMG 386 Placebo; Arm 4 Drug: Carboplatin
Arm 1 • Cohort 1: Lenabasum 5 mg twice per day (BID) (n = 118).<br/><br/>; Arm 2 • Cohort 2: Lenabasum 20 mg BID (n = 118).<br/>; Arm 3 • Cohort 3: Placebo BID (n = 118).